natgillin/translations-raw huggingface dataset:
The length of the latch sub relative to the jar mandrel is effectively adjustable, by reason of its upper end passing through a bulkhead in the lower end of the housing, the dimensions of the latch sub above the bulkhead and the aperture through which it passes being such as to prevent withdrawal of the latch sub downwardly through the bulkhead. 
Dužina elementa zasuna u odnosu na vreteno udaraca može se učinkovito podešavati, jer njegov gornji dio prolazi kroz masivnu glavu u donjem dijelu kućišta, a dimenzije elementa zasuna iznad masivne glave i otvor kroz koji prolazi su takve da spriječe izvlačenje elementa zasuna naniže kroz masivnu glavu.
For topical administration to the epidermis the compounds according to the invention can be formulated as ointments, creams or lotions, or as a transdennal patch. 
Za topičnu primjenu na epidermu spojevi prema izumu se mogu formulirati kao masti, kreme ili losioni, ili kao transdermalni naljepci.
The signal of which the average is calculated is delayed (S321). 
Pomnošti zakašnjeli signal u 54211 signal od kojeg je prosjek izračunatu S325.
converting at least one hydroxyl group of the polysaccharide into a blocking group, in accordance with claim 11; and 
(b) pretvaranje najmanje jedne hidroksilne skupine u polisaharidu u blokirajuću skupinu, u skladu s patentnim zahtjevom 11; 1
a protein-binding segment that interacts with said Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, and wherein said two complementary stretches of nucleotides are covalently linked by intervening nucleotides, and wherein (a) and (b) are in the same or separate containers. 
(ii) segment koji veže protein 1 koji međudjeluje s kimernim proteinom Cas9, pri čemu segment koji veže protein, obuhvaća dva komplementarna odsjeka nukleotida koji hibridiziranju za tvorbu dvostruke RNK strukture (AsRNK)-dupleks, te time, da su (a) i (b) u zajedničkom spremniku ili u odvojenim spremnicima.
Preferably, a composition of this disclosure is formulated for pharmaceutical use (“a pharmaceutical composition”), wherein the carrier is a pharmaceutically acceptable carrier. 
Smjesa prema zahtjevu 3 oblikovana za farmaceutsku primjenu 1 u kojoj je nosač farmaceutski prihvatljivi nosač.
R4, R5, R6 and R7 independently represent hydrogen, methyl or ethyl; and R11 independently represent hydrogen, halogen, amino, hydroxyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, cyclohexyl, phenyl, or a ring system from the group: thiophene, pyrrole, furane, pyrazole, tetrazole, oxazole, isoxazole, thiazole, pyrimidine and morpholino; 
ili R10 i R11 zajedno sa dva atoma ugljika koji ih nose predstavljaju heteroaril koji ima 5 ili 6 članova prstena ili heterociklilnu skupinu koja ima 5 ili 6 članova prstena, koja može biti zamijenjena s jednom od slijedećih skupina: halogen, hidroksi, nitro, cijano, trifluorometil, trifluorometoksi, C1-6alkil i C1-6alkoksi, naročito putem metila;
The method of clause 21 wherein step (2) comprises evaluating the acidic variants by a method selected from the group consisting of ion exchange chromatography wherein the composition is treated with sialidase, reduced capillary electrophoresis with sodium dodecyl sulfate (CE-SDS), non-reduced CE-SDS, boronate chromatography, and peptide mapping. 
Postupak prema zahtjevu 13 ili 14, naznačen time, da korak (2) obuhvaća procjenjivanje kiselinskih varijanti putem postupka koji je odabran iz skupine koju čine kromatografija ionske izmjene gdje se sastav obrađuje sa sialidazom, reducirana kapilarna elektroforezija s natrijevim dodecilsulfatom (CE-SDS), nereducirana CE-SDS, boronatna kromatografija i peptidno mapiranje.
Ra is hydroxy Rx is C1-4 alkyl or aryl A process for making a compound of formula (II), comprising the following step: wherein X, Y, Ra, PG1 and PG2 are as defined in claim 1. 
R* je hidroksi R, je Cr4 alkil ili aril. 2. | Postupak za pripremu spoja formule (II), koji sadrži sljedeći korak: ePEa d
Accordingly, a first aspect of the invention provides an immunogenic composition comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of the at least two further bacterial saccharide conjugates. Detailed description 
Imunogeni pripravak, naznačen time što sadrži konjugat saharida Hib i najmanje dva dodatna konjugata bakterijskih saharida, gdje konjugat Hib je prisutan u manjoj dozi saharida od srednje doze saharida za sve od najmanje dva dodatna konjugata bakterijskih saharida.
The cognitive disorders and diseases may be selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss. 
Farmaceutska kompozicija prema patentnom zahtjevu 6, naznačena time što su kognitivni poremećaji i bolesti izabrani iz grupe koju čine Alzheimer-ova bolest, oblici gubitka pamćenja i gubitak pamćenja povezan sa starošću.
wherein: is straight or branched chain alkyl or alkenyl group having from about 4 to about 30 carbon atoms; 
(D pri čemu R, je ravni ili razgranati lanac alkilne ili alkenilne skupine koja ima 4 do 30 atoma ugljika;
The ball screw 48 is driven in opposed directions by the motor 50 causing the first and second nuts 56, 58 to reciprocate along the ball screw 48 toward and away from each other. 
Motor (50) pokreće kuglasti vijak (48) u suprotnim smjerovima i tako uzrokuje približavanje i udaljavanje prve i druge matice (56), (58) uzduž vijka.
The mixture has been maintained at 25-30°C under stirring conditions. 
Smjesa je održavana pri 25-30 *C uz miješanje.
A method of preparing a compound according to claim 1, comprising reacting an intermediate compound of formula (A2), (B2) or (C2): 
7. > Postupak za dobivanje spoja prema zahtjevu 1, naznačen time da navedeni postupak sadrži korak omogućavanja da intermedijarni spoj s općom formulom (B2):
A dispenser as claimed in claim 33, 34 or 35, further comprising a tolerance adjustment mechanism. 
Dispenzer prema zahtjevu 32, 33, 34 dalje sadrži mehanizam za prilagodbu tolerancije.
According to another preferred embodiment, the cancer is selected from the group consisting of breast cancer (including metastatic breast cancer), cervical cancer, colorectal cancer (including metastatic colorectal cancer), lung cancer (including non-small cell lung cancer), non-Hodgkins lymphoma (NHL), chronic lymphocytic leukemia, renal cell cancer, prostate cancer including hormone refractory prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, soft tissue cancer, gastrointestinal stromal tumor, glioblastoma multiforme and multiple myeloma. 
Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5betal, za uporabu prema zahtjevu 7, naznačen/i time, da je rak odabran iz skupine koju čine: rak dojke, rak cerviksa, kolorektalni rak, rak pluća, non- Hodgkinsov limfom (NHL), rak renalnih stanica, rak prostate, rak jetre, rak glave i vrata, melanom, rak jajnika, mezoteliom, rak mekog tkiva i višestruki mijelom.
reacting an intermediate of formula (XXIV) with potassium cyanide in the presence of a suitable solvent, With R1, R2 and n as defined in claim 1; 
reakcija intermedijera formule (XXIV) s kalijevim cijanidom u prisutnosti prikladnog otapala, [image] s R1, R2 i n kako su definirani u zahtjevu 1;
The compound or composition of paragraph 14, wherein the second therapeutic agent is selected from ritonavir, efavirenz, didanosine, tenofovir disoproxil, nelfinavir mesilate, amprenavir, raltegravir potassium, saquinavir, lopinavir, nevirapine, emtricitabine, abacavir, lamivudine, zidovudine, maraviroc, stavudine, darunavir, fosamprenavir, vicriviroc, a pharmaceutically acceptable salt of any of the foregoing, and combinations thereof 
Spoj ili kompozicija prema zahtjevu 16, gdje se drugo terapeutsko sredstvo bira od ritonavira, efavirenca, didanozina, tenofovir dizoproksila, nelfinavir mesilata, amprenavira, kalij raltegravira, sakvinavira, lopinavira, nevirapina, emtricitabina, abakavira, lamivudina, zidovudina, maraviroka, stavudina, darunavira, fosamprenavira, vicriviroca, farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih i njihovih kombinacija.
At day 4, the culture was transferred to a TCF175 cm2 and diluted to 120 mL by adding fresh and preheated medium SM-005. 
i razrijeđena na 120 mL dodatkom svježeg prethodno zagrijanog SM-005 medija.
as well as salts, N-oxydes, metallic complexes, metalloidic complexes and optically active or geometric isomers thereof. 
kao i njihove soli, N-oksidi, metalni kompleksi, metaloidni kompleksi i optički aktivni ili geometrijski izomeri.
simultaneously heating and pressing the stack of sheets to fuse points of contact between the nanofibres of adjacent sheets. 
istovremenog zagrijavanja i prešanja snopa listova radi spajanja kontaktnih točaka između nanovlakana susjednih listova, i
a first reversible electric motor operably associated with said invert base to rotate said invert base about said axis in a pair of opposed directions, and 
- prvi reverzibilni elektromotor (44) koji je operativno povezan sa spomenutom bazom invertiranja kako bi spomenutu bazu invertiranja zakretao oko spomenute osi u suprotnim smjerovima, te
wherein the piston retracts, thereby freeing the vertical motion of the motor, when the stem of the cutting head is to be lowered until the selected tool is brought down to a worktable. 
- < za povlačenje, oslobađajući vertikalno gibanje motora (25), kada se držak (30) mora spustiti dok se alat ne dovede do radnog stola (18).
a body (20) adapted to be disposed in the conduit, 
Trup (20) prilagođen tako da se može odložiti u cijev,
After a subsequent resting period of approximately 12 hours, the so formed block of wood was watered for another 24 hours at a temperature of approximately 80 °C in a water bath 40 (steamed). 
Nakon razdoblja mirovanja od približno 12 sati, koje je slijedilo iza toga, tako oblikovan blok od drva je bio potopljen u vodu kroz sljedeća 24 sata na temperaturi od približno 80"C u kupki za vodu 40 (parena voda).
Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. 
Injekcijske suspenzije se također mogu pripraviti tako da se u tom slučaju mogu upotrijebiti odgovarajući tekući nosači, tvari za suspendiranje i slično.
The method according to claim 2, wherein the interfacing layer (20) comprises a piece of non-woven fabric or a net, or a layer of sand. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što međusloj (20) sadrži komad netkane tkanine ili mrežu, ili
An electrically heated smoking system according to any of claims 1 to 5, wherein the one or more electrically conductive tracks are on the outside of the tube of electrically insulating substrate. 
Električno grijani sustav za pušenje u skladu s patentnim zahtjevom 1, 2 ili 3, naznačen time što se jedna ili više električno vodljivih tračnica (203) nalazi s vanjske strane cijevi od električno izolirajuće podloge (201).
The composition according to claim 17, wherein the composition is freeze-dried together with an excipient to increase stability of the antibody during and after freeze-drying. 
Smjesa prema zahtjevu 17, pri čemu je smjesa liofilizirana zajedno s pomoćnom tvari za povećanje stabilnosti protutijela tijekom liofilizacije.
The method according to Claim 15, wherein said antigen is loaded onto class II MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of said antigen with an antigen-presenting cell. 
Metoda prema Zahtjevu 13, gdje je antigen uklopljen u MHC molekule razreda II prikazan na površini prikladne stanice koja prikazuje antigen putem kontakta dovoljne količine antigena sa spomenutom stanicom.
The method of claim 9 wherein r is an integer from 2 to 9. 
n cijeli broj od 2 do 6; poželjno n je 4;
the binder is polyethylene glycol or polyvinylpyrrolidone, or a combination thereof, and is present at a concentration of about 5% to about 15% (w/w); 
vezivo je polietilen-glikol ili polivinil-pirolidon, ili njihova kombinacija, i nalazi se u koncentraciji od oko 5% do oko 15% (masa/masa);
In one aspect, the invention provides methods for treating or preventing a tumor, a cancer, and/or a cell proliferative disorder associated with increased expression and/or activity (signaling) of Notch1, the methods comprising administering an effective amount of an anti-Notch1 NRR antibody to an individual in need of such treatment. 
Anti-Notch1-NRR-protutijelo prema bilo kojem zahtjevu od 1 do 11, naznačeno time, da se upotrebljava u postupku liječenja pojedinca koji ima poremećaj povezan s povećanjem signalizacije Notch1, pri čemu postupak obuhvaća davanje djelotvorne količine spomenutog anti-Notch1-NRR-protutijela pojedincu, pri čemu taj poremećaj
Due to these properties, Meldonium (registered with the trade mark of “MILDRONĀTS®”, “MILDRONATE®”, “M POHAT®”) is extensively applied in medicine as an anti-ischemic un stress-protective drug in treating various cardio-vascular diseases and other pathologies involving tissue ischemia (R. S. Karpov, O. A. Koshelskaya, A. V. Vrublevsky, A. A. Sokolov, A. T. Teplyakov, I. Skarda, V. Dzerve, D. Klintsare; A. Vitols, I. Kalvinsh, L. Matveyeva, D. Urbane. 
Zbog tih svojstava, meldonij (registriran pod komercijalnim nazivom "MILDRONATS", "MILDRONATE", "MIIJIPOHAT") se naširoko primjenjuje u medicini kao anti-ishemijski lijek 1 lijek za zaštitu od stresa u liječenju raznih kardiovaskularnih bolesti i drugih patologija koje uključuju ishemiju tkiva (R.S. Karpov, O.A. Koshelskaya, A.V. Vrublevsky, A.A. Sokolov, A.T. Teplyakov, I. Skarda, V. Dzerve, D. Klintsare, A. Vitols, I. Kalvinsh, L. Matveyeva, D.
isolating a PUFA-enriched fraction from the polar fraction. 
- < izoliranje fosfolipida iz koncentrirane polarne frakcije.
In another example, the antibody or antigen binding fragment thereof increases a serum biomarker of bone deposition selected from the group consisting of as total alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, and type-I procollagen (C-terminal/N-terminal). In another example, the antibody or antigen binding fragment thereof inhibits bone resorption. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što protutijelo ili njegov ulomak koji veže antigen povećava biomarker seruma odlaganja kosti odabran iz skupine koju čine ukupna alkalna fosfataza, alkalna fosfataza specifična za kosti, osteokalcin, i prokolagen tip-I (C-terminalni/N-terminalni).
A delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and an inner layer, wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at about pH 5 or above, and wherein the inner layer comprises a third polymeric material which is a non-ionic polymer that is soluble in intestinal fluid, and at least one additive selected from a buffer agent and a base. 
Formulacija lijeka s produženim otpuštanjem za oralnu primjenu radi davanja lijeka u debelo crijevo pacijenta, pri čemu spomenuti pripravak sadrži: jezgro i prevlaku za jezgru, to jezgru koja sadrži lijek i ovojnicu koja sadrži vanjski sloj i unutarnji sloj; pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima prag pH na pH 6 ili više, i pri čemu unutarnji sloj sadrži treći polimerni materijal koji je neionski polimer koji je topljiv u crijevnoj tekućini, ili gastrointestinalnoj tekućini, i najmanje jedan aditiv odabran iz puferskog sredstva i baze.
The dental post according to at least one of the claims 1 to 7, characterized in that at least one longitudinal groove (5, 6, 7) is provided on the circumferential surface of said tapered portion, the course of said groove extending over part of the circumference of said post. 
Zubni most u skladu s najmanje jednim od patentnih zahtjeva 1 do 7, naznačen time što se na površini oboda navedenog ušiljenog dijela nalazi najmanje jedan uzdužni žlijeb (5, 6, 7), gdje se tijek navedenog žlijeba pruža preko dijela oboda navedenog mosta.
In one aspect of the present invention, in a method or use disclosed herein a patient is patient with type 2 diabetes mellitus (or type 2 diabetes mellitus patient), a patient treated for type 2 diabetes mellitus, a patient diagnosed with type 2 diabetes mellitus or a patient in need of treatment for type 2 diabetes mellitus. 
Empagliflozin za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je postupak za liječenje dijabetesa mellitus tipa 2 kod odraslog pacijenta ili za poboljšanje glikemijske kontrole kod odraslog pacijenta s dijabetesom mellitus tipa 2, gdje se empagliflozin primjenjuje oralno kod pacijenta u ukupnoj dnevnoj količini od 10 mg.
the toy article within the core defines a first toy article; removing a first one of the wrappers reveals a first one of the play objects, the first one of the play objects comprising a printed card; 
uklanjanje prvog od omotača (20, 40) otkriva prvi od igraćih objekata (30, 50, 66, 76, 86, 96), gdje prvi od igraćih objekata (30, 50, 66, 76, 86, 96) sadrži tiskanu karticu;
Methods and technology for the orientation of magnetic particles in coating compositions have been disclosed in the prior art, noteworthy in US 3,676,273; US 3,791,864; EP 406,667 B1; EP 556,449 B1; EP 710,508 A1 and WO 02/90002 A2; the latter being the closest prior art to the present application. 
Postupci i tehnologija za usmjeravanje magnetskih čestica u smjesama za premaz iva nje opisani su u dokumentima koji spadaju u stanje tehnike, a posebice u US 3,676,273; US 3,791,864; EP 406,667 B1; EP 556,449 B1; EP 710,508 Ali WO 02/90002 A2; potonji je dokument predmetnoj prijavi najbliže tehničko rješenje iz stanja tehnike.
wherein ring B and the pyrimidine to which it is fused form a ring system selected from wherein 
(1) naznačen time da prsten B 1 pirimidin na koji je kondenziran tvore prstenasti sustav odabran od
In the enclosed drawings the plate (3) acts as support for two electric sockets (C). 
U priloženim crtežima ploča (3) djeluje kao nosač za dvije električne utičnice (C).
Use of any of E 56 to 61, wherein the IL-17 antagonist is a bispecific antibody or bispecific antibody fragment that binds to and inhibits the activity of IL-17 and IL-23p19; or IL-17 and IL-23R. 
Uporaba u skladu s bilo kojim zahtjevom 56 do 61, naznačena time, da IL-17 antagonist je bispecifično antitijelo ili fragment bispecifičnog antitijela koje se veže na i inhibira djelovanje a) IL-17 i 1L-23p19, ili b) IL-1711L-23R.
treating Compound 9 with a lower alkyl carbonyl compound and a carbonate base in a biphasic solvent system to produce purified Compound 8; 
tretman spoja 9 sa C1 do C6 alkil karbonil spojem i karbonatnom bazom u bifaznom sustavu otapala da se proizvede prečišćeni spoj 8; i
Additional objects concern the development of processes for improving the solubility of chemical entities as complex as ET-743, eventually increasing the ET-743 concentration in the solution for lyophilising, and thus reducing the fill volume in the vials before lyophilising the formulation. 
Dodatni ciljevi odnose se na razvoj postupaka za poboljšanje topljivosti kemijskih entiteta kompleksnih kao ET-743, čime bi se eventualno postiglo povećanje koncentracije ET-743 u otopini za liofilizaciju, i na taj način smanjenje zapremine punjenja u ampulama prije liofilizacije oblika.
The method of preparation of metaxalone according to claim 14, where at the end of the phase of gradual temperature rise, an amount of base between 3 and 10 mol. % relative to the molar amount of TGIC present in the starting reaction solution, is added to the starting reaction solution. 
12.Postupak za proizvodnju metaksalona prema zahtjevu 11, naznačen time, da se na kraju faze postepenog povećavanja temperature, ponovno dodaje lužina u početnu reakcijsku otopinu, u količini od 3 do 10 molarnih %, poželjno od 5 do 8 molarnih %, u odnosu na molarnu količinu od TGIC koji je prisutan u početnoj reakcijskoj otopini.
a replacement of all or substantially all of the endogenous mouse heavy chain variable region gene locus with a plurality of human heavy chain variable region gene segments, wherein the human heavy chain variable region gene segments are operably linked to an endogenous mouse heavy chain constant gene, and the human heavy chain variable region gene segments are capable of rearranging and forming a rearranged human/mouse chimeric heavy chain gene. The mouse of claim 13, wherein: the mouse lacks an endogenous mouse k immunoglobulin light chain variable region locus that is capable of rearranging and forming a gene that encodes a mouse k variable region; 
zamjenu 90-100 % nepreuređenih mišjih segmenata gena VH s najmanje jednim nepreuređenim humanim segmentom gena VH i zamjenu svih endogenih mišjih segmenata gena D i JH s najmanje jednim nepreuređenim humanim segmentom gena D i najmanje jednim nepreuređenim ljudskim segmentom gena JH, pri čemu su humani segmenti gena VH, D i JH operativno povezani s endogenim mišjim konstantnim genom mišjeg teškog lanca, a humani segmenti gena VH, D i JH posjeduju sposobnost preuređivanja i formiranje preuređenog humanog/mišjeg kimernog gena teškog lanca.
Factor rFVIII as the protein of interest is separated and purified from the medium. 
Metoda iz patentnog zahtjeva 6 ili 7 pri čemu je protein od interesa rekombinantno proizvedeni rFVIII.
is a C2-6 alkenylene group or a C1-6 alkylene group optionally substituted by one or more hydroxy groups: and 
je C2-6 alkenilen skupina ili C1-6 alkilen skupina opcijski supstituirana s jednom ili više hidroksi skupina; i
A compound having the formula II: or a tautomer, enantiomer or salt, preferably a pharmaceutically acceptable salt thereof, wherein: 
Tvar koja ima formulu II: [image] ili njen tautomer, enantiomer ili sol, poželjno njena farmaceutski prihvatljiva sol, pri čemu:
The lighting module of claim 1, wherein said microchip is energized by a power source, wherein the energy of said power source depletes over time. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da se navedeni mikročip napaja iz izvora energije pri čemu se navedeni izvor energije s vremenom troši.
An immunogenic composition consisting essentially of a varicella zoster virus (VZV) gE antigen truncated to remove the carboxy terminal anchor region, which gE is not in the form of a fusion protein, in combination with an adjuvant comprising QS21, 3D MPL, and liposomes comprising cholesterol. 
Antigen VZV gE, skraćen kako bi se uklonilo C-terminalno sidrišno područje i koji nije u obliku fuzijskog proteina, namijenjen upotrebi u sprječavanju ili ublažavanju zone i/ili postherpetične neuralgije, naznačen time što antigen VZV gE treba primijeniti u kombinaciji s adjuvansom TH-1, koji sadrži QS21 1 3D MPL.
The tire curing press according to claim 1, wherein the indexing apparatus (120) is suspended from the movable platen (34), and is an indexing ring (122) which is rotatably mounted and comprises a plurality of steps that are circumferentially spaced on a bottom surface of the indexing ring (122). 
Preša za stvrdnjavanje gume prema zahtjevu 1, naznačena time daje uređaj za indeksiranje (120) suspendiran iz pokretne ploče (34) a indeksni prsten (122) koji je rotirajuće montiran sadrži veliki broj graničnika koji su kružno raspoređeni na donjoj površini taktnog prstena (122).
A pharmaceutical composition for use in a method of therapy, comprising an antibody which binds to a tumor-associated antigen, said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: 
Farmaceutska kompozicija za primjenu u terapeutskoj metodi, koja sadrži jednu ili više komponenti izabranih iz grupe koja se sastoji od: